$LABP News

Last published 6mo ago

6mo agoABBV LABPNImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBDBusiness WireNew data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans Supports the efficacy of NIM-1324, a de-risked,
7mo agoABBV LABPNImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026Business WireNovel findings to be presented at IMMUNOLOGY2026 demonstrate efficacy of novel LANCL2-targeting therapeutics outperforming current psoriasis treatments in multiple mouse models Newly discovered mechanisms in
2y agoABBV LABPAbbVie Completes Acquisition of Landos BiopharmaPR NewswireAbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP). With the completion of the...
2y agoKAMN LABP TGAN WRKKuehn Law Encourages LABP, WRK, KAMN and TGAN Investors to Contact Law FirmGlobeNewswireNEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
2y agoABBV LABPAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesPR NewswireAbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which AbbVie...
2y agoABBV LABPAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesGlobeNewswireNORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos") today announced a definitive agreement under which AbbVie will
2y agoLABPLandos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 ResultsGlobeNewswireTop-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into mid-2025 NEW YORK, March 21, 2024 (GLOBE
2y agoLABPLandos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn's and Colitis OrganisationGlobeNewswireNEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos" or the "Company"), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune
2y agoLABPLandos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn's and ColitisGlobeNewswireNX-13, a Novel, Oral, NLRX1 Agonist, was Observed to be Well Tolerated and Demonstrated Early Signs of Rapid Symptomatic Relief and Endoscopic Improvement in Patients with Ulcerative Colitis NEXUS Phase 2
3y agoLABPLandos Biopharma Provides Company Update and Reports Third Quarter 2023 ResultsGlobeNewswireNEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Remains On Track with Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, Nov. 09,
3y agoLABPLandos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific MeetingGlobeNewswireNEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that
3y agoLABPLandos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 CongressGlobeNewswireNX-13 Demonstrated Rapid Symptomatic Relief and Improvement in Multiple Biomarkers that Correlated With Early Endoscopic Response in Patients With Ulcerative Colitis (UC) NEXUS Phase 2 Clinical Trial is Ongoing;
3y agoLABPLandos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial CellsGlobeNewswireNEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a
3y agoLABPLandos Biopharma to Present at the 2023 Jefferies Healthcare ConferenceGlobeNewswireNEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that
3y agoLABPLandos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.GlobeNewswireNEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the
3y agoLABPLandos Biopharma Provides Business Update and Reports First Quarter 2023 ResultsGlobeNewswireNEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May 12, 2023 (GLOBE
3y agoLABPLandos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 ResultsGlobeNewswireOn Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024 Projected Cash Runway into First Half of 2025
3y agoLABPLandos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos' FounderGlobeNewswireTransaction Solidifies Company's Near-Term Strategic Focus on Advancing Clinical Development of NX-13 Company Remains On-Track to Initiate the NX-13 Phase 2 Proof-of-Concept Trial in Ulcerative Colitis in the Second
3y agoLABPLandos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn's and Colitis OrganizationGlobeNewswireNEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos" or the "Company"), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune
3y agoLABPLandos Biopharma Provides Comprehensive Update on Clinical Development PlansGlobeNewswireAdvancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024
3y agoLABPLandos Biopharma Announces $16.7 Million Private Placement FinancingGlobeNewswireNEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos" or the "Company"), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune
4y agoLABPLandos Biopharma Reports Third Quarter 2022 Results and Provides Business UpdateGlobeNewswireNEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced
4y agoLABPLandos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical OfficerGlobeNewswireNEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Fabio Cataldi, MD,
4y agoLABPLandos Biopharma Reports Second Quarter 2022 Results and Provides Business UpdateGlobeNewswirePositive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of Once-Daily Oral Doses, as well as Promising Early Efficacy Signals Phase 2 Proof of Concept Clinical Tria
4y agoLABPLandos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b TrialGlobeNewswireNX-13 Demonstrated Favorable Safety and Tolerability Profile Across Range of Once-Daily Doses Results Indicate Promising Early Signals Regarding the Efficacy of NX-13 Phase 2 Proof of Concept Clinical Trial in Ulcerative Colitis Planned NEW YORK
4y agoLABPLandos Names Gregory Oakes President and Chief Executive OfficerGlobeNewswireSeasoned Pharmaceutical Executive Brings 25+ Years of Experience With a Focus on Successful Commercialization Company Remains On Track to Complete Review of Clinical Development Plans Later This Year NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- L
4y agoLABPLandos Biopharma Reports First Quarter 2022 Results and Provides Business UpdateGlobeNewswireOn Track to Complete Review of Clinical Development Plans by Mid-2022 Top-Line Results for NX-13 Phase 1b and LABP-104 Phase 1 Trials Remain On Track for Mid-2022 Plans to Announce Timing of Phase 2b Trial of Omilancor Later this Year NEW YORK,
4y agoLABPLandos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business UpdateGlobeNewswireContinued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year Completed Enrollment of Phase 1b Trial of NX-13 in Ulcerative Colitis and Phase 1a Trial of LA
4y agoLABPLandos Biopharma Appoints Roger Adsett to its Board of DirectorsGlobeNewswireBLACKSBURG, Va., March 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it has appointed Roger Ads
4y agoLABPLandos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireEnhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical Development Plans for Omilancor to Generate Additional Phase 2b Data Prior to Initiating Pivotal Phase
5y agoLABPLandos Biopharma to Host Corporate Update CallGlobeNewswireBLACKSBURG, Va., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma Inc. (NASDAQ:LABP) today announced that it will report third quarter 2021 financial results and host a conference call to provide a corporate update on November 15, 2021. Following
5y agoLABPLandos Biopharma Announces Leadership TransitionGlobeNewswireJosep Bassaganya-Riera Steps Down as Chairman, President and CEO Tim M. Mayleben Appointed Interim President and CEO Chris Garabedian Appointed Chairman of the Board BLACKSBURG, Va., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma Inc
5y agoLABPLandos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid ArthritisGlobeNewswirePhase 1 trial is underway with topline results expected in the first half of 2022 Represents Landos' seventh IND cleared overall and the second IND cleared for LABP-104, a potentially first-in-class therapeutic candidate for systemic lupus erythematos
5y agoLABPLandos Biopharma Announces First Subject Dosed in a Phase 1 Study of LABP-104 for Systemic Lupus ErythematosusGlobeNewswireTopline results are expected in the first half of 2022 A whole blood LABP-104 precision medicine signature will be assessed during the trial BLACKSBURG, Va., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a late-clinical
5y agoLABPLandos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus ErythematosusGlobeNewswirePhase 1 trial initiation expected before yearend with topline results in 1H 2022 BLACKSBURG, Va., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE® Advanced
5y agoLABPLandos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor's Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 MechanismGlobeNewswireBLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmun
5y agoLABPLandos Biopharma to Participate in Truist Securities CEO Fireside Chat Series (Virtual)GlobeNewswireBLACKSBURG, Va., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® advanced A.I. platform to develop novel therapeutics for patients with autoimmune diseases,
5y agoLABPLandos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn's Disease with the Icahn School of Medicine at Mount SinaiGlobeNewswireSecond Phase 2 trial of omilancor in Crohn's disease (CD), expected to initiate in 2021 Awarded a $3 million NIH R01 grant from the U.S. National Institute of Diabetes and Digestive and Kidney Diseases to fund this study BLACKSBURG, Va., Sept. 20,
5y agoLABPLandos Biopharma to Present Results of LABP-104 in Lupus at the American College of Rheumatology Convergence 2021GlobeNewswireOral treatment with LABP-104 in preclinical models of Systemic Lupus Erythematosus (SLE) resulted in enhanced Treg function, decreased kidney inflammation and reduced interferon gamma signaling Phase 1 clinical trial anticipated to begin during Q4 202
5y agoLABPLandos Biopharma to Participate in Two Upcoming Investor Conferences in SeptemberGlobeNewswireBLACKSBURG, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune disea
5y agoLABPLandos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of MedicineGlobeNewswireBLACKSBURG, Va., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseas
5y agoLABPLandos Biopharma to Participate in Upcoming Investor EventsGlobeNewswireBLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseas
5y agoLABPLandos Biopharma Reports Second Quarter 2021 Financial Results and Provides Business UpdatesGlobeNewswireFollowing the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated global pivotal Phase 3 clinical trial site feasibility studies of omilancor in ulcerative colitis (UC) Initiated enrollment of Phase 2 trial of omilancor in Crohn's
5y agoLABPLandos Biopharma's Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation at the United European Gastroenterology Week 2021GlobeNewswireOmilancor shows efficacy and tolerability as a potential once-daily, oral, gut-restricted therapy for mild-to-moderate UC patients Following the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated clinical trial site feasibility stud
5y agoLABPLandos Biopharma to Present at the Raymond James Virtual Human Health Innovation ConferenceGlobeNewswireBLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoim
5y agoLABPLandos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis (UC) PatientsGlobeNewswireBLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE Advanced Artificial Intelligence (A.I.) platform to discover and develop novel oral therapeutic
5y agoLABPLandos Biopharma to Present at the Jefferies Virtual Healthcare ConferenceGlobeNewswireBLACKSBURG, Va., May 25, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune disea
5y agoLABP MRNS PFELandos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of DirectorsGlobeNewswireBLACKSBURG, Va., May 19, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ:LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appoin
5y agoLABPLandos Biopharma Reports First Quarter 2021 Financial Results and Provides Business UpdatesGlobeNewswireCompleted initial public offering of common stock, raising approximately $100 million in gross proceeds Following positive Phase 2 results of omilancor in ulcerative colitis, including statistically significant immunological and biomarker results, e
5y agoLABPLandos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian MarketsGlobeNewswireBLACKSBURG, Va., and SHANGHAI, China and PRINCETON, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ:LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoim